Piyawannarat S.Sirisreetreelux P.Rattapornsompong W.Tancharoen S.Viseshsindh W.Mahidol University2024-11-182024-11-182024-10-01Natural Product Communications Vol.19 No.10 (2024)1934578Xhttps://repository.li.mahidol.ac.th/handle/20.500.14594/102082Purpose: Evaluate the clinical efficacy of “Oriza tablet” (OT) for patients with neurologic bladder or overactive bladder affected by xerostomia due to receiving antimuscarinic drugs. Material and methods: This was a randomized clinical trial. Twenty-eight patients (median age = 64 years) with xerostomia were divided into two groups: OT (intervention group) and placebo (control) group. Both groups comprised 14 patients each. Objective: We assessed severity using a questionnaire for the subjective evaluation of xerostomia. Objective evaluation was undertaken for the stimulated salivary flow rate (SSFR). Xerostomia evaluation took place before treatment (baseline) as well as 2 weeks and 4 weeks after treatment. Results: The xerostomia score decreased significantly (p < 0.05) in the OT group compared to the placebo group, with scores of 2.75 versus 4.4 at 2 weeks and 2.19 versus 4.13 at 4 weeks, respectively. The SSFR increased significantly (p < 0.05) in the OT group compared to the placebo group, with SSFR of 2 versus 1.2 at 2 weeks and 1.85 versus 1.1 at 4 weeks, respectively. Throughout the trial, no patient discontinued taking antimuscarinic medications. There were no adverse effects noted. Conclusion: Continuous daily use of OT for 4 weeks reduced xerostomia symptoms and increased saliva production in patients suffering from neurologic bladder or overactive bladder who received antimuscarinic medications. Clinical trial registration: The study was registered with The Thai Clinical Trials Registry (TCTR). ID: TCTR20240715015.Pharmacology, Toxicology and PharmaceuticsAgricultural and Biological SciencesMedicineArticleSCOPUS10.1177/1934578X2412870652-s2.0-8520881369415559475